The following draft of certain rules further to amend the New Drugs and Clinical Trials Rules, 2019 which the Central

## Policy Analysis Report: Amendment to the New Drugs and Clinical Trials Rules, 2019 **1. Executive Summary:** This report analyzes a proposed amendment to the New Drugs and Clinical Trials Rules, 2019, as published in the Gazette of India on February 5, 2021. The core purpose of the amendment, based on the limited text provided, appears to be to broaden the scope of rule 2, subrule 1, clause (g) within the original rules by explicitly including the "analytical part" in addition to the "clinical part." This report details the specific change, identifies affected stakeholders, and infers potential outcomes based solely on the text of the amendment. **2. Introduction:** This report aims to provide a concise overview and analysis of the proposed amendment to the New Drugs and Clinical Trials Rules, 2019, published in the Gazette of India on February 5, 2021. The analysis is based solely on the provided policy text and aims to inform stakeholders about the specific changes being proposed. **3. Policy Overview:** * **Original Policy:** The New Drugs and Clinical Trials Rules, 2019 (G.S.R. 227E, dated March 19, 2019). * **Core Objective(s) (Inferred):** While the text does not explicitly state the overarching objectives of the original policy, it can be inferred that the policy aims to regulate new drugs and clinical trials within India. The proposed amendment suggests that this regulation extends to both clinical and analytical aspects. **4. Background and Rationale:** * **Amendment Rationale:** The amendment seems designed to clarify and potentially expand the regulatory purview of the New Drugs and Clinical Trials Rules, 2019. By explicitly including the "analytical part" alongside the "clinical part," the amendment likely addresses a perceived gap or ambiguity in the original rules regarding the regulatory oversight of analytical testing related to drugs and clinical trials. The reason for specifying this could be to bring more clarity to the scope and avoid loopholes. **5. Key Provisions / Changes:** * **Specific Part of Original Policy Changed:** Rule 2, subrule 1, clause (g) of the New Drugs and Clinical Trials Rules, 2019. * **New Rule/Provision:** The amendment inserts the words "or analytical part" after the words "clinical part" and before the words "or for both" in the specified clause. * **Difference/Effect of Change:** This insertion broadens the applicability of the rule to explicitly include the "analytical part" in addition to the "clinical part." This suggests that the rules now cover the testing and analysis of drugs and related substances involved in clinical trials, potentially impacting procedures and requirements related to analytical data, validation, and reporting. This could result in analytical studies needing to meet similar regulatory standards to clinical studies **6. Target Audience and Stakeholders:** Based on the provided text, the primary stakeholders directly affected by this amendment are: * Pharmaceutical companies involved in the research, development, and manufacturing of new drugs. * Clinical research organizations (CROs) conducting clinical trials. * Analytical testing laboratories involved in the analysis of drugs and related substances. * Regulatory bodies responsible for overseeing drug development and clinical trials, specifically the Ministry of Health and Family Welfare. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The Ministry of Health and Family Welfare (Department of Health and Family Welfare) is the responsible agency, with the Drugs Technical Advisory Board involved in the consultation process. * **Timelines/Procedures:** The amendment will come into force on the date of its final publication in the Official Gazette. A period of fifteen days is provided for public comments and suggestions before the draft rules are finalized. * **Amendment Specifics:** The changes will necessitate updates to relevant guidelines and procedures to reflect the inclusion of the "analytical part" within the regulatory framework. **8. Expected Outcomes / Impact of Changes:** * **Likely Intended Outcome of Changes:** The likely intended outcome of including the "analytical part" is to strengthen the regulatory oversight of analytical testing related to drugs and clinical trials. This could lead to: * Improved data quality and reliability in drug development. * Enhanced patient safety through more rigorous analytical testing. * Greater transparency and accountability in the drug approval process. * Potentially increased costs and timelines for drug development due to stricter analytical requirements. **9. Conclusion:** The proposed amendment to the New Drugs and Clinical Trials Rules, 2019, represents a potentially significant change by explicitly including the "analytical part" within its scope. While the full impact remains to be seen, it signals a commitment to enhanced regulatory oversight of the analytical aspects of drug development and clinical trials. Stakeholders should carefully review the final version of the amendment and adapt their practices accordingly to ensure compliance.

Key Entities Referenced